首页> 外文期刊>Plastic Surgery Case Studies >A 60-Year-Old Female With Metastatic Malignant Melanoma of the Scalp Responding to Ipilimumab
【24h】

A 60-Year-Old Female With Metastatic Malignant Melanoma of the Scalp Responding to Ipilimumab

机译:一个60岁的女性,头皮的转移性恶性黑色素瘤响应IPILIMIMAB

获取原文
           

摘要

Melanoma is an aggressive disease that accounts for approximately 75% of skin cancer-related deaths. In the past, treatment options for patients with advanced stage melanoma have been limited with poor response rate and failure to improve overall survival (OS). Immunotherapy is a promising treatment that has been shown to improve OS and in cases produce durable remissions—a novel concept in the treatment of advanced melanoma. We report a case of advanced stage metastatic malignant melanoma of the scalp with a durable (31 months) response to ipilimumab immunotherapy. This is the first case study reporting long-term, progression-free response to ipilimumab in metastatic melanoma without side effects of therapy. This case adds to the evidence supporting early referral and initiation of ipilimumab in patients who can tolerate it, with the goal of producing a sustained treatment-free response and preserved quality of life.
机译:黑色素瘤是一种侵略性的疾病,占皮肤癌症相关死亡的75%。 过去,对先进阶段黑素瘤的患者的治疗方案受到较差的反应率并且未能改善整体存活率(OS)。 免疫疗法是一种有前途的治疗,已被证明改善OS,并且在病例中产生耐用的剩余 - 一种新颖的心素瘤的概念。 我们通过对IPILIMIMAB免疫疗法的耐用(31个月)反应,举报了头皮的晚期阶段转移性恶性黑色素瘤的情况。 这是第一种研究报告长期,对Ipilemimab在转移性黑色素瘤中没有副作用的案例研究。 本例增加了支持能够容忍它的患者的早期转诊和启动IPILIMIMAB的证据,其目的是产生免持续治疗的响应和保存的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号